Optimising the use of the tripeptide feG for treatment of RSV bronchiolitis and subsequent airway hypersensitivity.
Chief Investigator: A/Prof Dani-Louise Dixon
Funding Amount : $99,973
Recipient: Flinders University
Overview: Bronchiolitis, the most common severe respiratory tract illness in infants, remains a major cause of hospitalisation in Australia. Currently, there is no treatment or vaccine against most causative viruses, including respiratory syncytial virus (RSV). Here we examine the therapeutic application of the anti-inflammatory tripeptide, feG, to treat RSV infection.